Inhibrx Biosciences Inc (INBX) Stock Price, Quote & News

Company Profile

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma,...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 795 4220

Website: inhibrx.com

Address:

11025 North Torrey Pines Road, Suite 140, La Jolla, United States

ArchieFarrer Oct. 25 at 3:01 PM

$INBX $MAMK ;;- https://stocktwits.com/ArchieFarrer/message/633704658

0 · Reply

topstockalerts Oct. 25 at 1:36 PM

Top Gainers $WGRX $INBX $GNTA $MAMK $NEUP

0 · Reply

SuperErica Oct. 25 at 1:30 AM

$EEIQ Top watch into next week, make sure to keep eyes on this one. Strong close. $WGRX $INBX $MAMK

0 · Reply

TrendTrade8696 Oct. 25 at 1:09 AM

$INBX Just in case anyone can't do the math. 19.5 Fully diluted sh's X $100 - $150 per share = $1,950,000,000 to $2,925,000,000.... THATS WHAT 109 will fetch in the next 90 -120 days!! HOME RUN!! THE DATA IS ALREADY OUT!!! IT WORKS!!

0 · Reply

TrendTrade8696 Oct. 25 at 12:44 AM

$INBX Tight float of only $14M. There will be NO DILUTION, NO SHELT, NO REGISTRATIONS!!! ***THEY DON"T NEED $$$$$.*** $186M in bank as of June 30th & 150m unused credit facility with Oxford. Co is selling the asset 109 in next 90 = 120 days & will prob fetch $100 - $150 per share. stk is cheap, it's a buy!!

1 · Reply

ap20 Oct. 25 at 12:43 AM

$INBX They sold their last drug for 1.6 Billion. I think they know what they are doing.

1 · Reply

basereport Oct. 24 at 10:45 PM

🚀 Strongest stocks of the day Start tracking these today using our free stock screener: https://base.report/screener?filter_key=IJQVaoxW $WGRX $INBX $GNTA $NEUP

0 · Reply

topstockalerts Oct. 24 at 10:29 PM

Top Gainers $WGRX $INBX $GNTA $MAMK $NEUP

0 · Reply

Dngang82 Oct. 24 at 9:46 PM

$PMI this is just warming up. The real party will be Monday. $INBX $GNTA

0 · Reply

stockRDA Oct. 24 at 9:17 PM

$AMRZ if you had fun with $INBX, just wait and see what $AMRZ does next.

0 · Reply

Inhibrx: Positive Ozekibart Data For Bone Cancer Leads To Q2 2026 BLA Filing

Oct 23, 2025, 6:39 PM EDT - 1 day ago

Inhibrx shares surge after bone cancer drug slows disease progression in trial

Oct 23, 2025, 4:05 PM EDT - 1 day ago

Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

Oct 22, 2025, 4:01 PM EDT - 2 days ago

Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts

Aug 13, 2025, 4:05 PM EDT - 2 months ago

Inhibrx Reports Second Quarter 2025 Financial Results

May 14, 2025, 4:05 PM EDT - 5 months ago

Inhibrx Reports First Quarter 2025 Financial Results

Apr 1, 2025, 4:05 PM EDT - 7 months ago

Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President

Mar 17, 2025, 4:05 PM EDT - 7 months ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Jan 21, 2025, 5:01 PM EST - 9 months ago

Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer

Jan 13, 2025, 4:15 PM EST - 10 months ago

Inhibrx Biosciences Announces Loan Agreement with Oxford Finance

Nov 14, 2024, 4:24 PM EST - 1 year ago

Inhibrx Biosciences Reports Third Quarter 2024 Financial Results

Nov 5, 2024, 11:45 AM EST - 1 year ago

Inhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique Platform

Nov 4, 2024, 4:00 PM EST - 1 year ago

Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation

Aug 27, 2024, 7:10 AM EDT - 1 year ago

Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are Buying

HNRG TCBI

Aug 13, 2024, 6:54 PM EDT - 1 year ago

Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Jun 7, 2024, 2:42 PM EDT - 1 year ago

Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi

Jun 5, 2024, 7:46 AM EDT - 1 year ago

Top 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX)

A EXAS TDOC

May 24, 2024, 4:00 PM EDT - 1 year ago

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi

May 10, 2024, 6:36 PM EDT - 1 year ago

Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off

May 9, 2024, 3:36 PM EDT - 1 year ago

INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX

SNY

May 8, 2024, 4:37 PM EDT - 1 year ago

Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger

Feb 28, 2024, 9:15 AM EST - 1 year ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Jan 23, 2024, 11:45 AM EST - 1 year ago

Sanofi To Acquire Inhibrx in $1.7 Billion Deal To Boost Rare Disease Drugs Pipeline

SNY

Jan 23, 2024, 5:39 AM EST - 1 year ago

Sanofi to Buy Rare-Disease Assets From Inhibrx

SNY

Jan 23, 2024, 1:32 AM EST - 1 year ago

France's Sanofi to buy U.S. drugs project INBRX-101 for about $2.2 bln

SNY

Jan 23, 2024, 1:30 AM EST - 1 year ago

Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline

SNY

Jan 23, 2024, 1:00 AM EST - 1 year ago

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

SNY

Nov 9, 2023, 4:00 PM EST - 2 years ago

Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Nov 2, 2023, 9:15 AM EDT - 2 years ago

Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

Oct 18, 2023, 4:00 PM EDT - 2 years ago

Inhibrx Announces Participation in Upcoming Scientific Conferences

Sep 19, 2023, 4:00 PM EDT - 2 years ago

Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada

Sep 1, 2023, 4:26 PM EDT - 2 years ago

Andreas Halvorsen's Firm Ups Inhibrx Stake

Aug 29, 2023, 9:00 AM EDT - 2 years ago

Inhibrx Announces $200 Million Private Placement Financing

Aug 17, 2023, 4:41 PM EDT - 2 years ago

Inhibrx: INBRX-101 Developments Constructive, Market-Generated Data Not So Much

Aug 7, 2023, 4:00 PM EDT - 2 years ago

Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

May 30, 2023, 9:00 AM EDT - 2 years ago

Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

May 8, 2023, 4:05 PM EDT - 2 years ago

Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Apr 26, 2023, 9:00 AM EDT - 2 years ago

Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials

Apr 13, 2023, 11:12 AM EDT - 2 years ago

Inhibrx: Undercovered Company With Good Potential

Mar 6, 2023, 4:05 PM EST - 2 years ago

Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results

Jan 4, 2023, 9:00 AM EST - 3 years ago

NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Candidates

Nov 18, 2022, 4:05 PM EST - 3 years ago

Inhibrx Announces Participation in Upcoming Investor Conference

Nov 16, 2022, 9:00 AM EST - 3 years ago

Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of Chondrosarcoma

Nov 7, 2022, 4:05 PM EST - 3 years ago

Inhibrx Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Oct 4, 2022, 8:00 AM EDT - 3 years ago

Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study

Oct 3, 2022, 4:30 PM EDT - 3 years ago

Inhibrx To Host Webcast to Announce Regulatory Pathway for INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency

Aug 15, 2022, 4:05 PM EDT - 3 years ago

European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma

Aug 8, 2022, 5:19 PM EDT - 3 years ago

Inhibrx Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

ArchieFarrer Oct. 25 at 3:01 PM

$INBX $MAMK ;;- https://stocktwits.com/ArchieFarrer/message/633704658

0 · Reply

topstockalerts Oct. 25 at 1:36 PM

Top Gainers $WGRX $INBX $GNTA $MAMK $NEUP

0 · Reply

SuperErica Oct. 25 at 1:30 AM

$EEIQ Top watch into next week, make sure to keep eyes on this one. Strong close. $WGRX $INBX $MAMK

0 · Reply

TrendTrade8696 Oct. 25 at 1:09 AM

0 · Reply

TrendTrade8696 Oct. 25 at 12:44 AM

1 · Reply

ap20 Oct. 25 at 12:43 AM

$INBX They sold their last drug for 1.6 Billion. I think they know what they are doing.

1 · Reply

basereport Oct. 24 at 10:45 PM

🚀 Strongest stocks of the day Start tracking these today using our free stock screener: https://base.report/screener?filter_key=IJQVaoxW $WGRX $INBX $GNTA $NEUP

0 · Reply

topstockalerts Oct. 24 at 10:29 PM

Top Gainers $WGRX $INBX $GNTA $MAMK $NEUP

0 · Reply

Dngang82 Oct. 24 at 9:46 PM

$PMI this is just warming up. The real party will be Monday. $INBX $GNTA

0 · Reply

stockRDA Oct. 24 at 9:17 PM

$AMRZ if you had fun with $INBX, just wait and see what $AMRZ does next.

0 · Reply

Maynard_Keysian Oct. 24 at 9:08 PM

$INBX Both of my AI tools suggest it is very likely they will be raising cash. I expect an offering soon.

1 · Reply

BennyBjammin Oct. 24 at 9:06 PM

$INBX See you at the crossroads, crossroads, crossroads So you won't be lonely

0 · Reply

BrunetteSara Oct. 24 at 8:47 PM

$CMCT Next nano floater runner!! Worth to watch ;) $GNTA & $INBX Did great today congrats bulls...

0 · Reply

Botaeng Oct. 24 at 8:39 PM

$INBX next week will have an offering.

1 · Reply

UnicornProfits Oct. 24 at 8:34 PM

What is happening to ticker CMCT right now?! CMCT is breaking out like crazy.. Are they pumping up ticker CMCT for 300% today!? Its insane what's going on in this market.. Looks like all eyes are moving to CMCT now.. Watching: $WGRX $INBX $GNTA $MAMK ----

0 · Reply

Henley22 Oct. 24 at 8:20 PM

$INBX ...and you think it'll go higher after just Phase 2 results?... congrats if you bought early this year and now taking your winnings. 🙂

1 · Reply

JohnKoban Oct. 24 at 8:19 PM

$INBX bought a bunch of put options. Sorry bulls ☺️

0 · Reply

BennyBjammin Oct. 24 at 8:09 PM

$INBX You will see this ownersip circle very seldom if ever. There are no 'Others'. Get on your board and ride the wave you goofy sleuth.

0 · Reply

topstockalerts Oct. 24 at 8:06 PM

Top Gainers $WGRX $INBX $MAMK $GNTA $NEUP

0 · Reply

BennyBjammin Oct. 24 at 7:57 PM

$INBX To all you bearish 'offering' derps

0 · Reply

ProfitKing Oct. 24 at 7:56 PM

$INBX offering when?

1 · Reply

Ryan4vp Oct. 24 at 7:55 PM

$INBX i could see them doing an offering here…and it would be smart since phase 3 takes a grundle of cash.

1 · Reply

Market Cap	410.79M
Revenue (ttm)	200,000.00
Net Income (ttm)	1.69B
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	843,784.96%
Debt to Equity Ratio	1.45

Volume	6,079,500
Avg Vol	286,320
Day's Range	N/A - N/A
Shares Out	14.49M
Stochastic %K	91%
Beta	0.51
Analysts	Hold
Price Target	$12.00